NCT01668719: Phase 1/2 - S1211 Bort, Dex & Lenalidomide +/- Elotuzumab High Risk NDMM SWOG 1211
FDA Approved for Multiple Myeloma treatment: Bortezomib (formerly PS-341) VELCADE SUBCUTANEOUSLY
NCT01464034: Phase 1/2 - Carfilzomib, Pomalidomide With Dexamethasone in Patients With RRMM
NCT01410500: Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With RRMM Myeloma
NCT01311687: Phase 3 - Efficacy & Safety of Pomalidomide & Low dose dex Vs High-Dose Dex - NIMBUS
NCT01454297: MMRF CoMMpass Study in Newly Diagnosed Multiple Myeloma - (CoMMpass)
NCT01402284: Phase 2 - Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients
NCT01346787: EMN - Phase 2: Carfilzomib, Cyclophosphamide and Dexamethasone Newly Diagnosed Myeloma
NCT01421524: Phase 1: Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness
NCT01415882: Phase 2: Ixazomib Citrate in Relapsed Multiple Myeloma, Not Refractory to Bortezomib
NCT01081028: Connect® MM- The Multiple Myeloma Disease Registry
NCT01239797: Phase 3: Lenalidomide and Dexamethasone With or Without Elotuzumab RRMM (ELOQUENT - 2)
NCT01208766: Phase 3 - EMN02 - Compare VMP With HDM f/b VRD Consol & Lenalidomide Maint. NDMM (HO95)
GMMG phase III trial ReLApsE Salvage autologous transplant and lenalidomide maintenance vs. len-Dex
NCT01093196: Phase 3: EMN01- Len/Dex Vs Melphalan/Pred/Len Vs Cyclophosamide/Pred/Len - elderly NDMM
NCT01155583: Phase 1/2: Low-Dose Azacitidine, Lenalidomide & Low-Dose Dexamethasone in RRMM Myeloma
NCT01208662- Phase 3 - DETERMINATION Trial: Delayed vs Early Transplant with RVd & Revlimid Maint.
NCT01080391: Comparing Carfilzomib, Lenalidomide & Dex (CRd) vs Lenalidomide and Dex (Rd) - ASPIRE
NCT01169337: Phase 3 -Lenalidomide or Observation in Asymptomatic High-Risk Smoldering Myeloma E3A06
NCT01134484: Phase 3 - VELCADE-Thal-Dex (VTD) vs Thal-Dex (TD) Incorporated Into Double ASCT NDMM
NCT01109004: Phase 3 - Stem Cell Transplant With Lenalidomide Maint. NDMM BMT CTN 0702 (STaMINA)
NCT01217957: Phase 1/2: A Study of Ixazomib in Combination With Lenalidomide and Low-Dex in NDMM
NCT01191060: Phase 3 - IFM 2009 - (IFM/DFCI2009) Conventional dose RVD to High-Dose + ASCT -NDMM
NCT01190787: Phase 2: EMN - Velcade/Melphalan/Pred or Velcade/Cycloposphamide/Pred or Velcade/Pred.